Literature DB >> 20511184

Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells.

Wei Yan1, Chunfa Qian, Peng Zhao, Junxia Zhang, Lei Shi, Jin Qian, Ning Liu, Zhen Fu, Chunshen Kang, Peiyu Pu, Yongping You.   

Abstract

Osteopontin (OPN) is widely overexpressed in various cancers, including gliomas, and plays an important role in tumorigenesis. However, the expression pattern and functions of OPN splice variants expressed in gliomas remain unclear. The aims of our current study were to examine the expression pattern and functions of OPN splice variants in gliomas. In present study, the mRNA levels of OPN splice variants are markedly increased in gliomas tissues, and all OPN splice variants were also found in U251 and U87 cells. Furthermore, knock-down and regain of function experiments were designed to explore the functions of OPN splice variants in U251 and U87 cells. Lentiviral vectors of OPN small interference RNA (siRNA) targeting all three endogenous mRNAs of OPN and OPN splice variants synonymous mutant that were not silenced by OPN siRNA were constructed. Our results showed that all OPN splice variants synonymous mutant-protected glioma cells from apoptosis induced by OPN siRNA through alteration of the levels of Bcl-2 family proteins and OPN-b Mu elicted a significant effect. Both OPN-a Mu and -c Mu promoted glioma cell invasion through alteration of the levels of uPA, MMP-2, and MMP-9 expressions and the activities of MMP-2 and MMP-9 via activation PI-3K/AKT/NF-kappaB signaling pathway. Moreover, OPN-c Mu showed the strongest effect on glioma cell invasion, while OPN-b Mu showed no effect on the invasion of U251 and U87 cells. Thus, different splice variants of OPN have divergent functions in regulating apoptosis and invasion of glioma cells, which broadens their importance in glioma biotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511184      PMCID: PMC2940675          DOI: 10.1093/neuonc/noq006

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

Review 1.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

Authors:  Jerry E Chipuk; Douglas R Green
Journal:  Trends Cell Biol       Date:  2008-03-07       Impact factor: 20.808

Review 2.  Mitochondrial dynamics and apoptosis.

Authors:  Der-Fen Suen; Kristi L Norris; Richard J Youle
Journal:  Genes Dev       Date:  2008-06-15       Impact factor: 11.361

3.  Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.

Authors:  Jia-Lin Lee; Mei-Jung Wang; Putty-Reddy Sudhir; Gen-Der Chen; Chin-Wen Chi; Jeou-Yuan Chen
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

4.  Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model.

Authors:  Virginie Lamour; Marie Le Mercier; Florence Lefranc; Martin Hagedorn; Sophie Javerzat; Andreas Bikfalvi; Robert Kiss; Vincent Castronovo; Akeila Bellahcène
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

5.  Correlation between osteopontin protein expression and histological grade of astrocytomas.

Authors:  H Toy; O Yavas; O Eren; M Genc; C Yavas
Journal:  Pathol Oncol Res       Date:  2008-12-02       Impact factor: 3.201

6.  Osteopontin-c is a selective marker of breast cancer.

Authors:  Mana Mirza; Elizabeth Shaughnessy; John K Hurley; Kristie A Vanpatten; Gary A Pestano; Bin He; Georg F Weber
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

7.  Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.

Authors:  Koviljka Matusan-Ilijas; Senija Behrem; Nives Jonjic; Kamelija Zarkovic; Ksenija Lucin
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

8.  Osteopontin prevents monocyte recirculation and apoptosis.

Authors:  Tricia H Burdo; Malcolm R Wood; Howard S Fox
Journal:  J Leukoc Biol       Date:  2007-03-16       Impact factor: 4.962

Review 9.  Osteopontin: regulation in tumor metastasis.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  Cancer Metastasis Rev       Date:  2008-03       Impact factor: 9.264

10.  Insights into the connection between cancer and alternative splicing.

Authors:  Eddo Kim; Amir Goren; Gil Ast
Journal:  Trends Genet       Date:  2007-12-03       Impact factor: 11.639

View more
  19 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1.

Authors:  Norihisa Nishimichi; Hiromi Hayashita-Kinoh; Chun Chen; Haruo Matsuda; Dean Sheppard; Yasuyuki Yokosaki
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

3.  Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells.

Authors:  Dah-Yuu Lu; Wei-Lan Yeh; Ssu-Ming Huang; Chih-Hsin Tang; Hsiao-Yun Lin; Shao-Jiun Chou
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

4.  Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Authors:  Yasuto Yamaguchi; Zhifei Shao; Shadi Sharif; Xiao-Yan Du; Timothy Myles; Milton Merchant; Griffith Harsh; Michael Glantz; Lawrence Recht; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

5.  Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.

Authors:  Jun Wei; Anantha Marisetty; Brett Schrand; Konrad Gabrusiewicz; Yuuri Hashimoto; Martina Ott; Zacharia Grami; Ling-Yuan Kong; Xiaoyang Ling; Hillary Caruso; Shouhao Zhou; Y Alan Wang; Gregory N Fuller; Jason Huse; Eli Gilboa; Nannan Kang; Xingxu Huang; Roel Verhaak; Shulin Li; Amy B Heimberger
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

6.  Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines.

Authors:  Rihua Zhang; Xiaolin Pan; Zuhu Huang; Georg F Weber; Guoxin Zhang
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

7.  Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.

Authors:  Antje Hahnel; Henri Wichmann; Thomas Greither; Matthias Kappler; Peter Würl; Matthias Kotzsch; Helge Taubert; Dirk Vordermark; Matthias Bache
Journal:  BMC Cancer       Date:  2012-04-02       Impact factor: 4.430

8.  Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.

Authors:  Brian C Baumann; Gary D Kao; Abdullah Mahmud; Takamasa Harada; Joe Swift; Christina Chapman; Xiangsheng Xu; Dennis E Discher; Jay F Dorsey
Journal:  Oncotarget       Date:  2013-01

9.  Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus.

Authors:  Ornella J Rullo; Jennifer M P Woo; Miriam F Parsa; Alice D C Hoftman; Paul Maranian; David A Elashoff; Timothy B Niewold; Jennifer M Grossman; Bevra H Hahn; Maureen McMahon; Deborah K McCurdy; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2013-01-23       Impact factor: 5.156

10.  Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer.

Authors:  Xiaojian Tang; Jianfang Li; Beiqin Yu; Liping Su; Yingyan Yu; Min Yan; Bingya Liu; Zhenggang Zhu
Journal:  Int J Biol Sci       Date:  2012-12-20       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.